Valneva announced that the European Commission (EC) has granted marketing authorization in Europe for Valneva’s single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older.
Toggle Navigation
- Research
Back- Research at Vienna BioCenter
- Research Entities
- Research AreasResearch AreasOpen SubmenuBack
- Anthropogenic Evolution
- Biochemistry, Biophysics, Structure
- Cell and Chromosome Biology
- Cognitive and Behavioral Biology
- Computational Biology, Genomes and Evolution
- Disease Mechanisms, Immunology, Pathogens
- Gene Regulation, RNA, Epigenetics
- Microbiology and Environmental Systems Science
- Neurobiology
- Plant Sciences
- Stem Cells, Development, Regeneration
- Research Groups
- Key DiscoveriesKey DiscoveriesOpen Submenu
- Recent Research Highlights
- VBCF
- Companies
Back- Companies at Vienna BioCenter
- Biotech CompaniesBiotech CompaniesOpen SubmenuBack
- Alpine Engineering
- a:head
- Ablevia biotech
- ADvantage Therapeutics
- aitiologic GmbH
- Akribes
- Austrianni
- Bio-LogX
- BioNTech R&D Austria
- Biosynth
- bit.bio discovery GmbH
- CALYXHA Biotechnologies
- ChanPharm
- dawn bio
- Elaris
- Discovery Evolution
- Epitome Therapeutics
- Eveliqure
- Fragrami
- HeartBeat.bio AG
- HOOKIPA Pharma Inc.
- JLP Health
- Lexogen
- Miti Biosystems
- Mobius Biotechnology
- MyeloPro Diagnostics and Research GmbH
- Myllia Biotechnology
- OncoOne
- Parallel Bio
- proxygen GmbH
- QUANTRO Therapeutics
- SCARLETRED
- Thermo Fisher Scientific
- Tridem Bioscience
- Valanx Biotech
- Valneva
- ViroTrust Diagnostics
- Viverita Discovery
- X4 Pharmaceuticals
- YGION Biomedical GmbH
- Service CompaniesService CompaniesOpen Submenu
- Business IncubatorsBusiness IncubatorsOpen Submenu
- Education
- Career
- About